Genetic factors in frontotemporal dementia: A review
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Shen, L. | - |
dc.contributor.author | Bagyinszky, E. | - |
dc.contributor.author | Youn, Y.C. | - |
dc.contributor.author | An, S.S.A. | - |
dc.contributor.author | Kim, S.Y. | - |
dc.date.available | 2020-02-29T01:41:36Z | - |
dc.date.created | 2020-02-12 | - |
dc.date.issued | 2013 | - |
dc.identifier.issn | 2005-9752 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/14938 | - |
dc.description.abstract | Frontotemporal dementia (FTD) is the second most common form of neurogenerative dementia, following Alzheimer's disease (AD). FTD is a clinically and phenotypically heterogeneous disorder, which occurs mostly in younger patients under 60 years of age. Several genes were described to be involved in FTD: progranulin (PGRN), microtubule-associated protein tau (MAPT), chromosome 9 open reading frame 72 (C9orf72), fused in sarcoma (FUS), TAR DNA binding protein-43 (TARDBP), valosin-containing protein (VCP), and charged multivesicular body protein 2B (CHMP 2B). Genome-wide association studies (GWAS) identified additional putative FTD risk factor genes, such as transmembrane protein 106B (TMEM106B) or ubiquilin-2 (UBQLN2). Improvements in genetic analysis could enhance the differential diagnosis for neurodegenerative disorders, especially FTD. This review summarized the FTD-associated genes, mutations and the latest methods for genetic analysis. © 2013 Korean Society of Environmental Risk Assessment and Health Science and Springer Science+Business Media Dordrecht. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.relation.isPartOf | Toxicology and Environmental Health Sciences | - |
dc.subject | charged multivesicular body protein 2B | - |
dc.subject | chromosome 9 open reading frame 72 | - |
dc.subject | fused in sarcoma | - |
dc.subject | peptides and proteins | - |
dc.subject | progranulin | - |
dc.subject | TAR DNA binding protein | - |
dc.subject | tau protein | - |
dc.subject | transmembrane protein 106B | - |
dc.subject | ubiquilin 2 | - |
dc.subject | unclassified drug | - |
dc.subject | valosin containing protein | - |
dc.subject | Alzheimer disease | - |
dc.subject | amyotrophic lateral sclerosis | - |
dc.subject | exon | - |
dc.subject | frontotemporal dementia | - |
dc.subject | gene mutation | - |
dc.subject | genetic association | - |
dc.subject | heredity | - |
dc.subject | human | - |
dc.subject | priority journal | - |
dc.subject | review | - |
dc.subject | risk factor | - |
dc.title | Genetic factors in frontotemporal dementia: A review | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.doi | 10.1007/s13530-013-0165-6 | - |
dc.identifier.bibliographicCitation | Toxicology and Environmental Health Sciences, v.5, no.3, pp.113 - 130 | - |
dc.identifier.scopusid | 2-s2.0-84886745901 | - |
dc.citation.endPage | 130 | - |
dc.citation.startPage | 113 | - |
dc.citation.title | Toxicology and Environmental Health Sciences | - |
dc.citation.volume | 5 | - |
dc.citation.number | 3 | - |
dc.contributor.affiliatedAuthor | Bagyinszky, E. | - |
dc.contributor.affiliatedAuthor | An, S.S.A. | - |
dc.type.docType | Review | - |
dc.subject.keywordAuthor | C9orf72 | - |
dc.subject.keywordAuthor | CHMP2B | - |
dc.subject.keywordAuthor | Dementia | - |
dc.subject.keywordAuthor | FTD | - |
dc.subject.keywordAuthor | FUS | - |
dc.subject.keywordAuthor | MAPT | - |
dc.subject.keywordAuthor | Mutation | - |
dc.subject.keywordAuthor | PGRN | - |
dc.subject.keywordAuthor | TARDBP | - |
dc.subject.keywordAuthor | VCP | - |
dc.subject.keywordPlus | charged multivesicular body protein 2B | - |
dc.subject.keywordPlus | chromosome 9 open reading frame 72 | - |
dc.subject.keywordPlus | fused in sarcoma | - |
dc.subject.keywordPlus | peptides and proteins | - |
dc.subject.keywordPlus | progranulin | - |
dc.subject.keywordPlus | TAR DNA binding protein | - |
dc.subject.keywordPlus | tau protein | - |
dc.subject.keywordPlus | transmembrane protein 106B | - |
dc.subject.keywordPlus | ubiquilin 2 | - |
dc.subject.keywordPlus | unclassified drug | - |
dc.subject.keywordPlus | valosin containing protein | - |
dc.subject.keywordPlus | Alzheimer disease | - |
dc.subject.keywordPlus | amyotrophic lateral sclerosis | - |
dc.subject.keywordPlus | exon | - |
dc.subject.keywordPlus | frontotemporal dementia | - |
dc.subject.keywordPlus | gene mutation | - |
dc.subject.keywordPlus | genetic association | - |
dc.subject.keywordPlus | heredity | - |
dc.subject.keywordPlus | human | - |
dc.subject.keywordPlus | priority journal | - |
dc.subject.keywordPlus | review | - |
dc.subject.keywordPlus | risk factor | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.